ABBV-6628

N/A

Report date: 2026/01/15 14:22:46

Base Information

Drug NameABBV-6628

Drug Alias NameABBV-6628

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionComplement C5 inhibitors

TargetsComplement C5

Therapy Area/IndicationsGeographic AtrophyMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc

Inactive CompaniesN/A

Active IndicationsGeographic AtrophyMacular Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeN/A